{"id":"NCT00499863","sponsor":"Noven Therapeutics","briefTitle":"Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD","officialTitle":"A Phase IIIb, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose Optimization Study, Designed to Evaluate the Efficacy and Safety of MTS in Adolescents Aged 13-17 Years With ADHD","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07","primaryCompletion":"2008-05","completion":"2008-05","firstPosted":"2007-07-12","resultsPosted":"2009-06-11","lastUpdate":"2017-04-26"},"enrollment":217,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["ADHD"],"interventions":[{"type":"DRUG","name":"methylphenidate transdermal system","otherNames":["DAYTRANA"]},{"type":"DRUG","name":"Placebo","otherNames":["Sham treatment"]}],"arms":[{"label":"Methylphenidate Transdermal System","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"To assess the efficacy and safety of efficacy of MTS compared to placebo","primaryOutcome":{"measure":"Change From Baseline in the Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Endpoint","timeFrame":"baseline and endpoint (up to 7 weeks)","effectByArm":[{"arm":"Methylphenidate Transdermal System","deltaMin":-18.8,"sd":1.01},{"arm":"Placebo (PTS)","deltaMin":-8.8,"sd":1.42}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.001"}]},"eligibility":{"minAge":"13 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":32,"countries":["United States"]},"refs":{"pmids":["20625364"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":145},"commonTop":["Decreased appetite","Headache","Upper respiratory tract infection","Irritability","Nausea"]}}